Hudson Bay Capital Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.09M | Buy |
450,000
+190,000
| +73% | +$3.59M | 0.02% | 416 |
|
|
2026
Q1 | $5.66M | Sell |
260,000
-15,000
| -5% | -$290K | 0.02% | 476 |
|
|
2025
Q4 | $5.92M | Buy |
275,000
+74,997
| +37% | +$1.58M | 0.02% | 459 |
|
|
2025
Q3 | $3.85M | Sell |
200,003
-68,097
| -25% | -$1.21M | 0.01% | 620 |
|
|
2025
Q2 | $4.58M | Buy |
268,100
+67,850
| +34% | +$2.89M | 0.02% | 564 |
|
|
2025
Q1 | $12.8M | Buy |
200,250
+135,250
| +208% | +$14.2M | 0.04% | 342 |
|
|
2024
Q4 | $7.9M | Hold |
65,000
| – | – | 0.03% | 409 |
|
|
2024
Q3 | $8.12M | Buy |
65,000
+57,500
| +767% | +$7.95M | 0.03% | 328 |
|
|
2024
Q2 | $1.19M | Buy |
+7,500
| New | +$963K | 0.01% | 590 |
|
|
2024
Q1 | – | Sell |
-88,208
| Closed | -$8.51M | – | 872 |
|
|
2023
Q4 | $8.51M | Buy |
88,208
+43,208
| +96% | +$4.14M | 0.05% | 208 |
|
|
2023
Q3 | $5.45M | Buy |
+45,000
| New | +$5.09M | 0.04% | 265 |
|
|
2023
Q1 | – | Sell |
-47,380
| Closed | -$6.14M | – | 981 |
|
|
2022
Q4 | $6.14M | Sell |
47,380
-122,620
| -72% | -$14.2M | 0.06% | 289 |
|
|
2022
Q3 | $18.8M | Sell |
170,000
-17,500
| -9% | -$1.76M | 0.17% | 77 |
|
|
2022
Q2 | $14.1M | Buy |
187,500
+145,000
| +341% | +$10.7M | 0.11% | 126 |
|
|
2022
Q1 | $3.32M | Buy |
+42,500
| New | +$3.25M | 0.04% | 538 |
|
|
2021
Q3 | – | Sell |
-37,500
| Closed | -$2.92M | – | 1076 |
|
|
2021
Q2 | $2.92M | Buy |
37,500
+9,500
| +34% | +$720K | 0.04% | 530 |
|
|
2021
Q1 | $2.09M | Buy |
+28,000
| New | +$2.58M | 0.03% | 540 |
|
|
2019
Q4 | – | Sell |
-45,000
| Closed | -$3.39M | – | 505 |
|
|
2019
Q3 | $3.39M | Buy |
+45,000
| New | +$5.31M | 0.09% | 201 |
|
|
2019
Q1 | – | Sell |
-10,000
| Closed | -$1.09M | – | 899 |
|
|
2018
Q4 | $1.09M | Hold |
10,000
| – | – | 0.01% | 623 |
|
|
2018
Q3 | $1.61M | Sell |
10,000
-10,000
| -50% | -$1.37M | 0.02% | 504 |
|
|
2018
Q2 | $2.64M | Buy |
+20,000
| New | +$1.89M | 0.04% | 444 |
|
|
2018
Q1 | – | Sell |
-170,400
| Closed | -$9.48M | – | 857 |
|
|
2017
Q4 | $9.48M | Sell |
170,400
-19,417
| -10% | -$1.03M | 0.2% | 82 |
|
|
2017
Q3 | $8.61M | Sell |
189,817
-40,866
| -18% | -$1.63M | 0.21% | 101 |
|
|
2017
Q2 | $7.78M | Sell |
230,683
-47,244
| -17% | -$1.54M | 0.16% | 135 |
|
|
2017
Q1 | $8.23M | Buy |
277,927
+110,836
| +66% | +$3.43M | 0.11% | 189 |
|
|
2016
Q4 | $4.58M | Sell |
167,091
-372,528
| -69% | -$15M | 0.1% | 210 |
|
|
2016
Q3 | $33.1M | Buy |
539,619
+84,619
| +19% | +$2.56M | 0.8% | 26 |
|
|
2016
Q2 | $8.68M | Buy |
+455,000
| New | +$8.43M | 0.27% | 68 |
|
Other funds holding SRPT
EAM
Hudson Bay Capital Management's SRPT Position: Q2 2026 in Review
Hudson Bay Capital Management increased its Sarepta Therapeutics (SRPT) stake by 73% in Q2 2026, buying an estimated $3.59M and bringing the position to 450,000 shares worth $8.09M. The position accounts for 0.02% of the portfolio, ranked #416.
Hudson Bay Capital Management first reported a position in SRPT in Q2 2016 and has held it in 28 quarters since. The position peaked at $33.1M in Q3 2016. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Hudson Bay Capital Management held 450,000 shares of Sarepta Therapeutics worth $8.09M as of Q2 2026.
- Hudson Bay Capital Management bought 190,000 Sarepta Therapeutics shares in Q2 2026, an estimated $3.59M.
- Sarepta Therapeutics made up 0.02% of Hudson Bay Capital Management's portfolio in Q2 2026, its #416 holding.
- Hudson Bay Capital Management first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 28 quarters since.
- Hudson Bay Capital Management's Sarepta Therapeutics position peaked at $33.1M in Q3 2016.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.